Cargando…
Therapeutic Implications of Renin–Angiotensin System Modulators in Alzheimer’s Dementia
The Renin–Angiotensin System (RAS) has attracted considerable interest beyond its traditional cardiovascular role due to emerging data indicating its potential involvement in neurodegenerative diseases, including Alzheimer’s dementia (AD). This review investigates the therapeutic implications of RAS...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10538010/ https://www.ncbi.nlm.nih.gov/pubmed/37765259 http://dx.doi.org/10.3390/pharmaceutics15092290 |
_version_ | 1785113228513116160 |
---|---|
author | Ababei, Daniela-Carmen Bild, Veronica Macadan, Ioana Vasincu, Alexandru Rusu, Răzvan-Nicolae Blaj, Mihaela Stanciu, Gabriela Dumitrița Lefter, Radu-Marian Bild, Walther |
author_facet | Ababei, Daniela-Carmen Bild, Veronica Macadan, Ioana Vasincu, Alexandru Rusu, Răzvan-Nicolae Blaj, Mihaela Stanciu, Gabriela Dumitrița Lefter, Radu-Marian Bild, Walther |
author_sort | Ababei, Daniela-Carmen |
collection | PubMed |
description | The Renin–Angiotensin System (RAS) has attracted considerable interest beyond its traditional cardiovascular role due to emerging data indicating its potential involvement in neurodegenerative diseases, including Alzheimer’s dementia (AD). This review investigates the therapeutic implications of RAS modulators, specifically focusing on angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), and renin inhibitors in AD. ACEIs, commonly used for hypertension, show promise in AD by reducing angiotensin (Ang) II levels. This reduction is significant as Ang II contributes to neuroinflammation, oxidative stress, and β-amyloid (Aβ) accumulation, all implicated in AD pathogenesis. ARBs, known for vasodilation, exhibit neuroprotection by blocking Ang II receptors, improving cerebral blood flow and cognitive decline in AD models. Renin inhibitors offer a novel approach by targeting the initial RAS step, displaying anti-inflammatory and antioxidant effects that mitigate AD degeneration. Preclinical studies demonstrate RAS regulation’s favorable impact on neuroinflammation, neuronal damage, cognitive function, and Aβ metabolism. Clinical trials on RAS modulators in AD are limited, but with promising results, ARBs being more effective that ACEIs in reducing cognitive decline. The varied roles of ACEIs, ARBs, and renin inhibitors in RAS modulation present a promising avenue for AD therapeutic intervention, requiring further research to potentially transform AD treatment strategies. |
format | Online Article Text |
id | pubmed-10538010 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-105380102023-09-29 Therapeutic Implications of Renin–Angiotensin System Modulators in Alzheimer’s Dementia Ababei, Daniela-Carmen Bild, Veronica Macadan, Ioana Vasincu, Alexandru Rusu, Răzvan-Nicolae Blaj, Mihaela Stanciu, Gabriela Dumitrița Lefter, Radu-Marian Bild, Walther Pharmaceutics Review The Renin–Angiotensin System (RAS) has attracted considerable interest beyond its traditional cardiovascular role due to emerging data indicating its potential involvement in neurodegenerative diseases, including Alzheimer’s dementia (AD). This review investigates the therapeutic implications of RAS modulators, specifically focusing on angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), and renin inhibitors in AD. ACEIs, commonly used for hypertension, show promise in AD by reducing angiotensin (Ang) II levels. This reduction is significant as Ang II contributes to neuroinflammation, oxidative stress, and β-amyloid (Aβ) accumulation, all implicated in AD pathogenesis. ARBs, known for vasodilation, exhibit neuroprotection by blocking Ang II receptors, improving cerebral blood flow and cognitive decline in AD models. Renin inhibitors offer a novel approach by targeting the initial RAS step, displaying anti-inflammatory and antioxidant effects that mitigate AD degeneration. Preclinical studies demonstrate RAS regulation’s favorable impact on neuroinflammation, neuronal damage, cognitive function, and Aβ metabolism. Clinical trials on RAS modulators in AD are limited, but with promising results, ARBs being more effective that ACEIs in reducing cognitive decline. The varied roles of ACEIs, ARBs, and renin inhibitors in RAS modulation present a promising avenue for AD therapeutic intervention, requiring further research to potentially transform AD treatment strategies. MDPI 2023-09-06 /pmc/articles/PMC10538010/ /pubmed/37765259 http://dx.doi.org/10.3390/pharmaceutics15092290 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Ababei, Daniela-Carmen Bild, Veronica Macadan, Ioana Vasincu, Alexandru Rusu, Răzvan-Nicolae Blaj, Mihaela Stanciu, Gabriela Dumitrița Lefter, Radu-Marian Bild, Walther Therapeutic Implications of Renin–Angiotensin System Modulators in Alzheimer’s Dementia |
title | Therapeutic Implications of Renin–Angiotensin System Modulators in Alzheimer’s Dementia |
title_full | Therapeutic Implications of Renin–Angiotensin System Modulators in Alzheimer’s Dementia |
title_fullStr | Therapeutic Implications of Renin–Angiotensin System Modulators in Alzheimer’s Dementia |
title_full_unstemmed | Therapeutic Implications of Renin–Angiotensin System Modulators in Alzheimer’s Dementia |
title_short | Therapeutic Implications of Renin–Angiotensin System Modulators in Alzheimer’s Dementia |
title_sort | therapeutic implications of renin–angiotensin system modulators in alzheimer’s dementia |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10538010/ https://www.ncbi.nlm.nih.gov/pubmed/37765259 http://dx.doi.org/10.3390/pharmaceutics15092290 |
work_keys_str_mv | AT ababeidanielacarmen therapeuticimplicationsofreninangiotensinsystemmodulatorsinalzheimersdementia AT bildveronica therapeuticimplicationsofreninangiotensinsystemmodulatorsinalzheimersdementia AT macadanioana therapeuticimplicationsofreninangiotensinsystemmodulatorsinalzheimersdementia AT vasincualexandru therapeuticimplicationsofreninangiotensinsystemmodulatorsinalzheimersdementia AT rusurazvannicolae therapeuticimplicationsofreninangiotensinsystemmodulatorsinalzheimersdementia AT blajmihaela therapeuticimplicationsofreninangiotensinsystemmodulatorsinalzheimersdementia AT stanciugabrieladumitrita therapeuticimplicationsofreninangiotensinsystemmodulatorsinalzheimersdementia AT lefterradumarian therapeuticimplicationsofreninangiotensinsystemmodulatorsinalzheimersdementia AT bildwalther therapeuticimplicationsofreninangiotensinsystemmodulatorsinalzheimersdementia |